This antibody is directed at cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death 1 ligand 1 (PD-L1) receptors; it initiates immune cell function, and normalizes the tumor microenvironment (Bellmunt et al., 2017; Borghaei et al., 2015; Robert et al., 2015). The gene discussed is CTLA4; the disease is neoplasm.